Venture Valuation together with KPMG and EuropaBio has published its most recent report at BIO in San Francisco in June 2016. The data for the cluster analysis is from Biotechgate (www.biotechgate.com), the global Biotech and Life Sciences database. According to the report, there are three types of European countries attractive to locate key value drivers … Continue reading Life Sciences clusters in Europe Report 2016
See our exclusive 2015 analysis we did for the Genesis conference (organized by our partner Onenucleus). Download cluster report »
Singapore / Taipei, June 2015 – Venture Valuation owned Biotechgate announces the partnership with Taiwan Bio Industry Organization to create a directory of Taiwanese Biotech companies. The database is the launch of a collaborative promotion of BIO Taiwan, one of the key Biotech and Life Sciences events in Asia. The Taiwanese Biotech Directory (www.taiwanesebiotech.com and … Continue reading Biotechgate/Venture Valuation partners with Taiwan BIO
This webinar provides insight into unique methods employed when valuing products and companies in Biotech. Speakers include Patrik Frei (Venture Valuation), David Thomas (BIO) et. al.
Venture Valuation presented a preview of its new report together with KPMG “Site Selection for Life Sciences Companies: Cluster Report 2015” in January at three locations including during JPMorgan in San Francisco, in Singapore and Taipei in February. The new report will be published in May 2015. For a copy of the key slides, please … Continue reading Preview. Site Selection for Life Sciences Companies: Cluster Report 2015
Big acquisitions like the recent purchase by Roche, Switzerland of Intermune, USA or AbbVie‘s successful USD 54bn bid for Shire, Ireland, are very good examples of how valuation metrics work and also show that often its not just about price. In case of AbbVie/Shire, potential tax saving was probably the key deal driver. In the … Continue reading Biotech Product Valuation – Setting a Price for Acquisitions
September 2014: Financing is an ongoing challenge for all Biotech companies. Without sufficient resources, products cannot be advanced in the development. Scarce resources help companies to focus as it is more important to bring one or two products into the clinic than advancing five different programs in pre-clinical development. But many European companies are struggling … Continue reading How to raise sufficient funds for Biotechs?
Venture Valuation recently published an article in Nature Biotechnology 32, 617–619, (2014) based on data from its Biotechgate deals database looking at the difference between big pharma and SMEs in the upfront payments and number of deals. Read more here (Nature Biotechnology) To get access to Biotechgate, please contact us here. Source: Nature Biotechnology, 32, … Continue reading The premium of a big pharma license deal
Marketing alliances between well-known brand names and consumer products have long been a tradition for example Michael Jackson and Pepsi or George Clooney and Nespresso. Soccer clubs are also dependent on sponsor income and are working with many different industries like telecoms, airlines and insurances. Now prestigious Manchester United (Man U) has signed a marketing … Continue reading Soccer and Pharma/BIOtech
Orphan drugs have been en vogue for a while. However, in the last quarter there has been a record financing that has put drugs for small patient populations on the map even more. In Q1 2014, over 60% of the financing in European Biotech has gone to companies that have a lead orphan drug product. … Continue reading Is Orphan saving Biotech?
